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 Introduction: Snakebite is a neglected tropical disease causing many 
deaths and serious consequences in Asia and Africa. Anti-snake Venom 
(ASV) is effective to prevent or reverse the venomous effects of 
snakebites. The aim of this study was to identify the prevalence of 
venomous snakebites and factors associated with treatment outcomes in 
a district hospital of Western Terai in Nepal. 
 
Method: A single health facility-based retrospective cross-sectional study 
was conducted with collection of information from the record section of 
Bhim Hospital, Rupandehi, Nepal. All snakebite cases treated during July 
2013 to July 2018 were included. The data on prevalence of snakebite and 
treatment outcomes were analyzed. Fischer’s exact test and exact logistic 
regression were performed to identify factors associated with treatment 
outcomes of venomous snakebites. 
 
Result: The prevalence of venomous snakebites was 3.71% (163/4399). 
Among cases with complete information (N=120), two-third were cured, 
and one-fourth were referred. Median number of ASV vials used was 12. 
Age and ASV vials used showed significant positive moderate correlation 
(r=0.38, p-value<0.001). Year of treatment showed significant association 
with treatment outcomes. In multivariate analysis, though insignificant, 
higher adjusted odds of cure was present with one unit increase in ASV 
vial (AOR= 1.16) and when the bite was in extremities (upper extremities 
AOR = 11.46 and lower extremities AOR= 21.68). 
 
Conclusion: Snakebite cases require urgent management with 
administration of ASV, and proper recording of the cases in order to 
provide tangible evidence for policy and guideline formulation. 
 
Keywords: anti-snake venom (ASV), district hospital, prevalence, 
snakebite, treatment outcomes 
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Snakebite was reinstated as a neglected 
tropical disease by World Health Organization 
on 9th June 2017.1 Annually, nearly two million 
people are envenomed by snakes in Asia and 
an estimated 435,000 to 580,000 snakebite 
cases need treatment in Africa. Out of these, 
most deaths and serious consequences are 
preventable by Anti-snake Venom (ASV), the 
only effective treatment to prevent or reverse 
the venomous effects of snake bites.2 
 
Vipers, Kraits and Cobras are the venomous 
snakes found in Nepal which are distributed as 
per geography and climate.3 In developing 
countries, identification of snake species is  
primarily made from the snake brought by the 
victim’s relatives.4 Traditional health seeking 
behavior as well as non-optimal access to 
health care decreases the true reporting of 
envenomation cases in developing countries.5 
This study aimed to identify the prevalence of 
venomous snakebite cases arriving in a district 
hospital of Western Terai of Nepal and factors 





The study was a single health facility-based 
retrospective cross-sectional study done at 
Bhim hospital, Rupandehi. Data was collected 
from the record section of Bhim hospital. All 
snakebite cases treated during July 2013 to 
July 2018 were included.  
 
Ethical approval for the study was obtained 
from Institutional Review Committee of Patan 
Academy of Health Sciences, Lalitpur, Nepal 
[Ref: std1903011245]. Written consent for the 
study was acquired from Bhim hospital 
administration. Anonymity was ensured during 
data collection by not including the name of 
patients and collected information was saved 
in a password-protected folder of the 
researcher’s password protected laptop to 
maintain privacy. 
 
Snakebite cases who were administered ASV in 
the hospital and had complete data were 
included in the study. 
 
Operational definitions used for analysis in this 
study, include- 
• Cured: Those ASV administered snakebite 
cases in whom the signs and symptoms of 
envenomation was reversed and were 
discharged from the hospital. 
• Dead: Those ASV administered snakebite 
cases who did not survive even after 
administration of ASV. 
• Referred: Those ASV administered 
snakebite cases who were asked by the 
health personnel to visit tertiary care 
centre for further management. 
• Anti-snake Venom (ASV): Lyophilized, 
Polyvalent Enzyme refined Equine 
immunoglobulin supplied to the public 
health facilities by Government of Nepal. 
• Venomous snakebite cases: All snake bites 
cases with Anti-snake Venom 
administered in the hospital. 
• Dependent and Independent age group: 
The age group are divided as dependent 
(less than 15 years and 60 years and above) 
and independent (15 to 59 years) as per 
Population Monograph of Nepal 2014.6 
• Snake species: Snake species were divided 
into Cobra, Krait and Unknown based on 
signs identified in patients, verification 
mark or killed snake brought by the patient 
or patient parties that were reported by 
the health care workers of the hospital. 
• Year of treatment: Snakebite cases of 5 
years were taken from July 2013 to July 
2018 and each 12 months from July 2013 
were stratified as year 1, 2, 3, 4 and 5 of 
treatment. 
 
Data were entered and cleaned in MS Excel for 
Windows 7 and were analyzed by Stata 
software version 13.0 and EZR version 1.36. 
Level of significance was set at 5% with p-value 
<0.05 being considered as statistically 
significant. Prevalence of venomous snakebite 
cases and frequencies for different variables 
are presented as descriptive analysis. Fisher’s 
exact test was used to find association 
between independent and dependent 
variables. Exact logistic regression was 
performed to find the odds for treatment 
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There were 163 venomous snakebite cases 
(3.71% of 4399 bites) in five years, of which 
110 (67.8%) got cured, 16 (9.82%) died and 32 
(22.7%) had to be referred, Table 1. Complete 
sets of data for analysis were available in 120 
cases, mean±SD age was 30.73±16.79 (male: 
28.37±17.11, female: 32.87±16.35) and 
median number of ASV vials used was 12 
(lowest: 3; highest: 29). Age and ASV vials used 
showed significant positive moderate 
correlation (r=0.38, p-value<0.001).  
 
In 120 cases with complete data, 88 (73.33%) 
were of independent age group, females more 
than males, snake species unknown in more 
than half, bite on lower extremities nearly half, 
three-fifth had more than 10 ASV vials, year 
five had maximum cases, and two-third cases 
got cured, Table 2. 
 
 
Table 1. Prevalence and outcome of venomous snakebite cases in a district hospital of Western Terai in Nepal 
 
 
Year Total snakebite 
cases 
Venomous cases  
(% of total) 
Cured (% of 
venomous cases) 
Dead (% of 
venomous cases) 
Referred (% of 
venomous cases) 
1 695 30 (4.32) 24 (80) 5 (16.67) 1 (3.33) 
2 874 30 (3.43) 20 (66.67) 3 (10) 7 (23.33) 
3 1042 36 (3.45) 26 (72.22) 5 (13.89) 5 (13.89) 
4 924 29 (3.14) 18 (62.07) 2 (6.90) 9 (31.03) 
5 864 38 (4.40) 22 (57.90) 1 (2.63) 15 (39.47) 
Total 4399 163 (3.71) 110 (67.48) 16 (9.82) 37 (22.70) 
 
Table 2. Descriptive analysis of venomous snake bite cases in a district hospital of Western Terai in Nepal 
 
 
Variables Number Percentage 
Age group Dependent 32 26.67 
 Independent 88 73.33 
Sex Male 57 47.50 
 Female 63 52.50 
Snake species Cobra 30 25.00 
 Krait 27 22.50 
 Unknown 63 52.50 
Site of bite Head and Neck 5 4.17 
 Abdomen and Back 2 1.67 
 Upper Extremities 54 45.00 
 Lower Extremities 59 49.17 
Total ASV used Less than or equal to 10 50 41.67 
 More than 10 70 58.33 
Treatment year Year 1 25 20.83 
 Year 2 21 17.50 
 Year 3 24 20.00 
 Year 4 23 19.17 
 Year 5 27 22.50 
Treatment Outcome Cured 80 66.67 
 Dead 9 7.50 
 Referred 31 25.83 
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Fisher’s exact test was done between 
independent and dependent variables which 
showed no association of age group, sex, snake 
species, site of bite and total ASV used with 
treatment outcomes, Table 3. Only the 
variable year of treatment showed significant 
association (p-value <0.05) with treatment 
outcomes, Table 3. 
 
As sample size for success (cured cases=1) 
and failure (dead cases=0) of treatment was 
less than 100 (N=89) and there were no 
samples in outcome “dead cases” in sub-
groups of different variables, dichotomous 
treatment outcomes were compared using 
bivariate and multivariate exact logistic 
analysis, which provided the Odds Ratio ( OR)  
and Adjusted Odds Ratio (AOR), Table 4. 
Independent variables with p-value less than 
or equal to 0.25 in bivariate analysis,7 and with 
Variance Inflation Factor (VIF) less than 2 were 




Table 3. Association between Treatment outcomes and independent variables of snakebite cases in a district 
hospital of Western Terai in Nepal 
 
Variables Treatment Outcomes p value 
Cured N (%), 
Expected Counts 
Dead N (%), 
Expected Counts 
Referred N (%), 
Expected Counts 
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Table 4. Exact logistic regression, bivariate and multivariate analysis (dependent variable- outcome: cured=1, 
dead=0) of snakebite cases in a district hospital of Western Terai in Nepal 
 
Independent Variables Odds Ratio (95% CI) P* Adjusted Odds Ratio p* value 
Age 1.01 (0.97-1.06) 0.642   
ASV vials used 1.15 (0.99-1.39) 0.076** 1.16 (0.99-1.40) 0.060 
Sex  0.604 (overall)   
Male Ref    
Female 0.53 (0.08-2.69) 0.604   
Site of bite  0.176(overall)**   
Head and neck Ref  Ref  
Abdomen and back 0.50* (0.01-Infinity) 1.000 0.49*(0.01-Infinity) 1.000 
Upper extremities 6.66 (0.08-580.18) 0.525 11.46 (0.10-1341.86) 0.424 
Lower extremities 12.27 (0.13-1123.22) 0.329 21.68 (0.18-2616.57) 0.253 
Species of snake  1.0 (overall)   
Cobra Ref    
Krait 3.05* (0.31-Infinity) 0.359   
Unknown 1.07 (0.16-5.67) 1.000   
Treatment year  0.566 (overall)   
First Ref    
Second 2.11 (0.15-119.87) 0.941   
Third 0.81 (0.10-6.88) 1.000   
Fourth 0.93 (0.09-12.54) 1.000   
Fifth 2.39*(0.24-Infinity) 0.480   




The study identified the prevalence of 
venomous snake bite in patients visiting a 
district hospital of Western Terai in Nepal  with 
suspicion of snake bite as 3.71% and the 
mortality of 9.82% among the envenomed 
patients after treatment. This outcome is 
similar to the range reported in studies from 
Southern India.8 Independent age group 
populations were bitten more often which 
corresponds to the results from different 
studies done in India and elsewhere.4,9,10 This 
study showed that more females (52.5%) were 
bitten by venomous snakes that contradicts 
the findings of a survey conducted in Nepal,12 
which may be because of increased migration 
of males from Nepal in recent times.6 Snake 
species being unknown and common site of 
bite being extremities matches with the 
findings from different studies.8,10 A clinico-
epidemiological study of snakebite done in 
Nepal has identified that high prevalence of 
snakebites being from unknown snakes was 
either due to ignorance of patients who were 
bitten, poor visibility in the dark or unable to 
spot the snake when in fields with tall grasses 
and crops.13 Three in five venomous snakebite 
cases were administered more than 10 ASV 
vials, which is in line with the National 
Guideline for snakebite management in Nepal. 
The guideline recommends that 10 vials of ASV 
should be administered with intravenous 
infusion at the rate of 2 ml per minute over 40-
60 minutes followed by 5 vials of ASV 
intravenous push at the rate of 2 ml per minute 
if signs of envenomation do not diminish.14 
 
No significant results were identified from 
bivariate exact logistic regressions, but within 
the study population there were higher odds of 
cure (OR= 1.01) with increasing age which 
opposed the result from study in West Bengal.9 
In present study, as there was significant 
positive correlation between age and ASV vials 
used but the amount of venom delivered by a 
snake is similar in each bite, thus higher odds 
of cure with increasing age can be justified. A 
hospital based retrospective epidemiological 
study on snake bites in two districts of Nepal 
has also identified higher mortality in lower 
age group owing to delivery of greater amount 
of toxin per kilogram body weight.12 Females 
had lower odds of cure (OR= 0.53) which was 
similar to the findings from studies conducted 
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odds of cure (OR= 3.05) was present when the 
snake species was Krait which was contrary to 
the findings from different studies done in 
India.16,17 This may be due to absence of 
mortality of patients bitten by Krait in this 
study. In this study, highest odds of cure were 
present in the 5th year (OR=2.39) which may be 
due to greater number of referred cases, and 
no reported mortality.  
 
In multivariate analysis, though insignificant, 
higher adjusted odds of cure (AOR= 1.16) was 
present with one unit increase in ASV vial 
controlling for site of bite and when the bite 
was in extremities (Upper extremities AOR = 
11.46 and Lower extremities AOR = 21.68) 
controlling for number of ASV vials 
administered. Exact dose of ASV to be 
administered in cases of snake envenomation 
is still a matter of discussion, with some studies 
showing insignificant association between 
cure and ASV dose administered.18 However, 
early administration of ASV to reduce snake 
bite related morbidity and mortality have been 
suggested by different studies.19,20,21,22  
 
Some of the limitations of present study are- a 
single health facility-based study, thus the 
result cannot be generalized. Many variables 
that could be associated with treatment 
outcomes such as time of bite, time to reach 
hospital, status of first aid, use of local 
measures, signs and symptoms after the bite 
etc. could not be assessed because they were 
not mentioned in the record. About one-fourth 
recorded data were incomplete and could not 
be included in the analysis which may have 






Significant association between year of 
treatment and treatment outcomes, with 
increased with increased referrals in recent 
years were identified from the study data. 
Though insignificant, the study identified 
different factors like increase in age, male sex, 
ASV vials used, bite on extremities and bite by 
Krait to have higher likelihood to be cured. The 
reasons as “why” the referred rate is increasing 
from a public hospital and “why” the recording 
and reporting of snake bite cases are 
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